RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells

Published:2010-03-27 Issue:8 Volume:59 Page:1173-1183
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Borkner Lisa,Kaiser Andrew,van de Kasteele Willeke,Andreesen Reinhard,Mackensen Andreas,Haanen John B.,Schumacher Ton N.,Blank Christian

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-010-0842-0.pdf

Reference30 articles.

1. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233–240

2. June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117:1466–1476. doi: 10.1172/JCI32446

3. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R (2006) Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24:5060–5069. doi: 10.1200/JCO.2006.07.1100

4. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99:16168–16173

5. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, Kubi A, Shalmon B, Hardan I, Catane R, Segal E, Markel G, Apter S, Nun AB, Kuchuk I, Shimoni A, Nagler A, Schachter J (2009) Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J Immunother 32:415–423

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Visualized photodynamic nanomaterials activating tumor-associated immune landscape as a next-generation anticancer strategy;Coordination Chemistry Reviews;2024-10

2. PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy;Journal of Nanobiotechnology;2024-07-27

3. A review of PD-1/PD-L1 siRNA delivery systems in immune T cells and cancer cells;International Immunopharmacology;2022-10

4. Tumor accomplice: T cell exhaustion induced by chronic inflammation;Frontiers in Immunology;2022-09-02

5. Non-viral siRNA delivery to T cells: Challenges and opportunities in cancer immunotherapy;Biomaterials;2022-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3